Clinical trials: Head and Neck Cancers
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Head and Neck Cancer
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00281840
- Testing
- bevacizumab, docetaxel, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258310
- Testing
- capecitabine, Surgery, chemotherapy and/or radiotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Thyroid Carcinoma
Trial of LBH589 in Metastatic Thyroid Cancer
The purpose of this study is to evaluate the tumor response rate in patients with metastatic medullary thyroid cancer (MTC) or radioiodine resistant differentiated thyroid cancer (DTC) after receiving treatment with LBH589 20 mg…
- Trial name
- NCT01013597
- Testing
- LBH589
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.
- Trial name
- EXTAX (NCT03887442)
- Testing
- Paclitaxel, Cetuximab + Paclitaxel
- Volunteers
- 17 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Squamous Cell Carcinoma
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).
- Trial name
- NCT00443261
- Testing
- Azacitidine, Cisplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Kansas Medical Center
Basal Cell Carcinoma, Squamous Cell Carcinoma
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
The primary objective of this study is to (1) determine whether local injection of lidocaine used during Mohs surgery will elevate serum lidocaine concentrations to a level that could cause systemic symptoms and (2) determine…
- Trial name
- NCT00793169
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Esophageal Cancer
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as cetuximab may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00096031
- Testing
- cetuximab
- Where
- 152 sites in United States
- Volunteers
- 63 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086996
- Testing
- fluorouracil, oxaliplatin, conventional surgery
- Where
- 143 sites in United States
- Volunteers
- 98 people
- Sponsor
- SWOG Cancer Research Network
Barrett Esophagus, Esophageal Cancer
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
This randomized phase II trial is studying the effect of esomeprazole magnesium and aspirin on tissue PGE2 levels compared with esomeprazole and placebo.
- Trial name
- NCT00474903
- Testing
- acetylsalicylic acid, esomeprazole magnesium
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
HNSCC
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition (phosphatidylinositol-3-kinase/ mammalian target of…
- Trial name
- HNSCC (NCT03740100)
- Testing
- Bimiralisib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Parathyroid Diseases, Parathyroid Dysfunction
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
The goal of this study is to assess whether using PTeye (AiBiomed, Santa Barbara, CA) - a NIRAF detection modality - can improve patient outcomes and reduce healthcare associated costs after parathyroid surgeries.
- Conditions
- Parathyroid Diseases, Parathyroid Dysfunction, Parathyroid Neoplasms, Parathyroid Adenoma
- Trial name
- NCT05152927
- Testing
- Parathyroid Eye (PTeye)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Francisco
Carcinoma, Squamous Cell, Head and Neck Cancer
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Patients will receive standard of care radiation therapy to the primary tumor of the head and neck and involved nodal metastasis and draining nodal basin and either weekly cisplatin or every 3-week cisplatin in locally advanced…
- Trial name
- NCT02994069
- Testing
- Cisplatin, XRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Susanne Arnold
Head and Neck Cancer
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00720083
- Testing
- cisplatin, vandetanib, radiation therapy
- Where
- 63 sites in United States
- Volunteers
- 34 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Esophageal Cancer
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal…
- Trial name
- NCT00393068
- Testing
- Erlotinib, Bevacizumab, Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.